Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics In Surgery ›› 2021, Vol. 21 ›› Issue (06): 675-678.DOI: 10.3969/j.issn.1009-976X.2021.06.018

• Case Report • Previous Articles     Next Articles

The successful application of inetetamab combined with pyrotinib in the treatment of HER-2 positive advanced breast cancer: a case report

GUI Xiu-juan, ZHAO Jian-li, WANG Ying, CHAI Jie, DIN Lin-xiao-xiao, YAO He-rui   

  1. Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
  • Contact: YAO He-rui, yaoherui@mail.sysu.edu.cn

伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌1例

桂秀娟, 赵健丽, 汪颖, 柴洁, 丁林潇潇, 姚和瑞*   

  1. 中山大学孙逸仙纪念医院乳腺肿瘤中心,广州 510120
  • 通讯作者: * 姚和瑞,Email:yaoherui@mail.sysu.edu.cn
  • 基金资助:
    国家自然科学基金(82071754)

Abstract: Approximately 15%~20% of patients with metastatic breast cancer have HER2-positive disease, which isassociated with more aggressive disease biology and historically, a poorer prognosis relative to other molecular subtypes. The application of trastuzumab has greatly improved patients outcomes,however, trastuzumab-resistance is common. We presented a HER-2 positive metastatic breast cancer case, who was diagnosed as primary trastuzumab resistance and successfully treated with inetetamab combined with pyrotinib and eribulin.

Key words: inetetamab, pyrotinib, trastuzumab-resistance, HER2 positive breast cancer

摘要: HER2阳性乳腺癌约占所有乳腺癌的15%~20%,其侵袭性强且预后较差。曲妥珠单抗的应用显著改善了患者的预后,但仍有部分患者会出现曲妥珠单抗耐药。本文报道一例应用“伊尼妥单抗”联合“吡咯替尼”及“艾立布林”后疗效显著的曲妥珠单抗原发耐药的晚期乳腺癌患者。

关键词: 伊尼妥单抗, 吡咯替尼, 曲妥珠单抗耐药, HER2阳性乳腺癌

CLC Number: